INMED (INM) Falls Short of Nasdaq Equity Rule Ahead of Mentari Merger
InMed reported shareholders' equity of $1.08 million, below Nasdaq's $2.5 million minimum, and says its pending merger with Mentari should restore compliance.
InMed Pharmaceuticals (INM) has received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market, notifying the company that its shareholders' equity of $1,075,007, as reported in its Form 10-K for the fiscal year ended June 30, 2026, fell below the $2.5 million minimum required for continued listing on The Nasdaq Capital Market under Listing Rule 5550(b)(1).
